Analyzing a New Mechanism in Response to Tamoxifen Therapy in Breast Cancer Patients

Inclusion Criteria

• •1. The patient must consent to be in the study and must have signed an approved consent form conforming to institutional guidelines
• •2. The patient must be 18 years or older.
• •3. Core biopsy should definitively demonstrate invasive carcinoma.
• •4. Invasive carcinoma should be ER-apha receptor positive
• •5. The tumor should be approximately at least 1 cm, to account for variability in imaging and imaging occult disease (physical exam, mammography, ultrasound). We recognize that from time to time because of this variation, there might not be enough tissue available for analysis after surgical excision but this will allow the greatest opportunity to capture as many eligible patients as possible.
• •6. Patients in whom surgical excision of the tumor is part of standard of care management
• •7. ECOG score of 0 or 1
• •8. Negative serum or urine beta-hCG pregnancy test at screening for patients of child-bearing potential (this is routinely done if the patient is premenopausal and having surgery)
• •9. Consent to participate in DBBR (RPCI only)